Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Stroke. 2019 Nov 20;51(1):129–136. doi: 10.1161/STROKEAHA.119.027085

Table 2.

Cancer-Specific Treatment and Laboratory Values

Treatment Value
Chemotherapy 45 (56%)*
Radiation therapy 13 (16%)
 Average Gy 3600 (2225–6450)
Treatment stage
 First line 32 (40%)
 Recurrence 43 (54%)
 Pre-treatment 5 (6%)
Coagulopathy
 Platelets 90,000 (17,500–211,500)
 INR 1.16 (1.08–1.40)
 PT 12.9 (11.6–15.2)
 PTT 30.0 (25.6–32.1)
Transfusions 41 (51%)
 PRBC 3 (3.8%)
 Platelets 38 (48%)
 FFP 6 (7.5%)
 Cryoprecipitate 1 (1.25%)
30-day mortality 29 (36%)

Gy indicates Gray; INR, international normalized ratio; PT, prothrombin time; PTT, partial thromboplastin time; PRBC, packed red blood cells; and FFP, fresh frozen plasma.

*

Categorical variables are presented as N (%).

Continuous variables are presented as median (interquartile range).